Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, will provide Moores Cancer Center at UC San Diego Health with molecular sequencing, analysis and decision support tools to enable further research on immune checkpoint inhibitors across cancer types.
“We are pleased to support Moores Cancer Center as it works to further incorporate genomic data into their clinical and research practice,” said Eric Lefkofsky, Co-founder and CEO of Tempus. “Collecting and analyzing patients’ molecular, treatment and outcome data will be transformative for patients, researchers and the healthcare ecosystem.”
Moores Cancer Center is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers in the U.S. The center is committed to innovation, and is developing and testing the effectiveness of new therapies and medical devices in fields including personalized therapy, immunotherapy, minimally invasive surgeries, and more.
Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers.
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.